Management of silicone granuloma: A systematic review

• Type of Material: Article
• Authors: Danielle E. Mustin, Emory University; Devon L. Barrett, Emory University; Ameya Gangal, Emory University; Mia S. White, Emory University; Howa Yeung, Emory University
• Language: English
• Date: 2023-06-01
• Publisher: Elsevier
• Publication Version: Final Published Version
• Copyright Statement: Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.
• License: Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1016/j.jdin.2022.12.006
• Title of Journal or Parent Work: JAAD International
• Volume: 11
• Start Page: 41
• End Page: 42
• Grant/Funding Information: Dr Yeung is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases under award numbers L30AR076081 and K23AR075888. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or US Department of Veterans Affairs.
• Keywords: silicone injection; foreign-body reaction; granuloma; adverse event; management

Abstract

To the Editor: In 2017, the US Food and Drug Administration issued warnings against injectable silicone for cosmetic enhancement.1 Despite well-established associations between silicone injection and granuloma formation, current evidence-based management guidelines are limited.2,3 The current guidelines by the American Society of Dermatologic Surgery recommend “intralesional injections of 5-FU (5-fluorouracil) mixed with triamcinolone at monthly intervals” for the treatment of silicone granulomas, with low certainty of evidence.3 We aimed to characterize treatments and associated outcomes for silicone granulomas following silicone injection.